Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of syndrome X.
The SHROB rat is a unique strain with genetic obesity, hypertriglyceridemia, hyperinsulinemia, renal disease with proteinuria, and genetically determined hypertension, characteristics paralleling human Syndrome X. The obese phenotype results from a single homozygous recessive trait, designated faK, and is allelic with the Zucker fatty trait (fa), but of distinct origin. The faK mutation is a premature stop codon in the extracellular domain of the leptin receptor, resulting in a natural receptor knockout. The SHROB are glucose intolerant compared to heterozygous or wild-type SHR, but retain fasting euglycemia even on a high sucrose diet, suggesting that diabetes requires polygenic interaction with additional modifier genes. Insulin-stimulated phosphorylation of tyrosine residues on the insulin receptor and on the associated docking protein IRS-1 are reduced in skeletal muscle and liver compared to SHR, due mainly to diminished expression of insulin receptor and IRS-1 proteins. Despite multiple metabolic derangements and severe insulin resistance, hypertension is not exacerbated in SHROB compared to SHR. Thus, insulin resistance and hypertension are independent in this model. Increased activity of the sympathetic nervous system may be a common factor leading by separate pathways to hypertension and to insulin resistance. We studied the chronic effects of sympathetic inhibition with moxonidine on glucose metabolism in SHROB. Moxonidine (8 mg/kg/day), a selective I1-imidazoline receptor agonist, not only reduced blood pressure but also ameliorated glucose intolerance. Moxonidine reduced fasting insulin by 47% and plasma free fatty acids by 30%. Moxonidine enhanced expression and insulin-stimulated phosphorylation of IRS-1 in skeletal muscle by 74 and 27%, respectively. Thus, central sympatholytic therapy not only counters hypertension but also insulin resistance, glucose tolerance, and hyperlipidemia in the SHROB model of Syndrome X.
Ernsberger
P
P
Department of Nutrition, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106-4935, USA.
Koletsky
R J
RJ
Friedman
J E
JE
D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology; D002352:Carrier Proteins / Q000378:metabolism; D004195:Disease Models, Animal; D004703:Endocrine System / Q000503:physiopathology; D005260:Female; D006946:Hyperinsulinism / Q000209:etiology / Q000378:metabolism; D006949:Hyperlipidemias / Q000209:etiology / Q000378:metabolism; D006973:Hypertension / Q000209:etiology / Q000378:metabolism; D007093:Imidazoles / Q000494:pharmacology; D055504:Insulin Receptor Substrate Proteins; D007333:Insulin Resistance; D007674:Kidney Diseases / Q000209:etiology / Q000378:metabolism; D020738:Leptin / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism*; D008297:Male; D009765:Obesity / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D010641:Phenotype; D010750:Phosphoproteins / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D051381:Rats; D011922:Rats, Mutant Strains; D011972:Receptor, Insulin / Q000378:metabolism; D011956:Receptors, Cell Surface; D054411:Receptors, Leptin
D019440:Anti-Obesity Agents; D002352:Carrier Proteins; C526292:IRS1 protein, human; D007093:Imidazoles; D055504:Insulin Receptor Substrate Proteins; C526296:Irs1 protein, rat; D020738:Leptin; D010750:Phosphoproteins; D011956:Receptors, Cell Surface; D054411:Receptors, Leptin; C043482:moxonidine; D011972:Receptor, Insulin